[New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy].
暂无分享,去创建一个
D. Bernard | G. Lambeau | C. Girard | B. Seitz-Polski | D. Vindrieux | Guillaume Dolla | Arnaud Augert
[1] A. Tedgui,et al. [Lp-PLA2 and sPLA2: cardiovascular biomarkers]. , 2014, Medecine sciences : M/S.
[2] C. Ponticelli,et al. Glomerular diseases: membranous nephropathy--a modern view. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[3] D. Bernard,et al. PLA2R1 kills cancer cells by inducing mitochondrial stress. , 2013, Free radical biology & medicine.
[4] M. Gelb,et al. PLA2R1 mediates tumor suppression by activating JAK2. , 2013, Cancer research.
[5] J. Wetzels,et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[6] L. McWilliam,et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. , 2013, Kidney international.
[7] J. Campisi. Aging, cellular senescence, and cancer. , 2013, Annual review of physiology.
[8] G. Eisenhofer,et al. Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells , 2012, BMC Cancer.
[9] J. Wetzels,et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.
[10] M. Stegall,et al. The Pathology and Clinical Features of Early Recurrent Membranous Glomerulonephritis , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[11] H. Debiec,et al. Pathogenesis of membranous nephropathy: recent advances and future challenges , 2012, Nature Reviews Nephrology.
[12] E. Rondeau,et al. Autoantibodies Specific for the Phospholipase A2 Receptor in Recurrent and De Novo Membranous Nephropathy , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] David M. Beck,et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.
[14] David M. Beck,et al. Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[15] L. Kiemeney,et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. , 2011, The New England journal of medicine.
[16] H. Debiec,et al. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. , 2011, The New England journal of medicine.
[17] R. Stahl,et al. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. , 2010, The New England journal of medicine.
[18] Kei Yamamoto,et al. Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. , 2010, Biochimie.
[19] D. Bernard,et al. [Senescent-associated factors: pro- and anti-tumoral actions]. , 2009, Medecine sciences : M/S.
[20] David M. Beck,et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.
[21] D. Bernard,et al. The M‐type receptor PLA2R regulates senescence through the p53 pathway , 2009, EMBO reports.
[22] Kwang Seok Kim,et al. Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through an ROS-mediated p53 pathway. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.
[23] A. Dejean,et al. [A review of cellular senescence: friend or foe of tumorigenesis?]. , 2009, Medecine sciences : M/S.
[24] M. Gelb,et al. Biochemistry and physiology of mammalian secreted phospholipases A2. , 2008, Annual review of biochemistry.
[25] James G. Bollinger,et al. Importance of group X–secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model , 2007, The Journal of experimental medicine.
[26] M. Gelb,et al. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. , 2007, Biochemistry.
[27] C. Isacke,et al. The mannose receptor family. , 2002, Biochimica et biophysica acta.
[28] H. Arita,et al. Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2. , 2002, Prostaglandins & other lipid mediators.
[29] J. Haymann,et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. , 2002, The New England journal of medicine.
[30] H. Arita,et al. Identification of a Soluble Form Phospholipase A2Receptor as a Circulating Endogenous Inhibitor for Secretory Phospholipase A2 * , 2002, The Journal of Biological Chemistry.
[31] N. Fujii,et al. Enhanced tissue expression and elevated circulating level of phospholipase A(2) receptor during murine endotoxic shock. , 2000, Archives of biochemistry and biophysics.
[32] M. Lazdunski,et al. Receptors for a growing family of secreted phospholipases A2. , 1999, Trends in pharmacological sciences.
[33] M. Lazdunski,et al. Both Group IB and Group IIA Secreted Phospholipases A2 Are Natural Ligands of the Mouse 180-kDa M-type Receptor* , 1999, The Journal of Biological Chemistry.
[34] J. Fayard,et al. Nuclear location of PLA2-I in proliferative cells. , 1998, Journal of cell science.
[35] H. Arita,et al. Resistance to Endotoxic Shock in Phospholipase A2 Receptor-deficient Mice* , 1997, The Journal of Biological Chemistry.
[36] M. Lazdunski,et al. Endocytic Properties of the M-type 180-kDa Receptor for Secretory Phospholipases A(*) , 1996, The Journal of Biological Chemistry.
[37] M. Lazdunski,et al. Identification of the Binding Domain for Secretory Phospholipases A2 on Their M-type 180-kDa Membrane Receptor * , 1995, The Journal of Biological Chemistry.
[38] M. Lazdunski,et al. Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2. , 1995, Biochemistry.
[39] M. Lazdunski,et al. The Human 180-kDa Receptor for Secretory Phospholipases A2 , 1995, The Journal of Biological Chemistry.
[40] M. Lazdunski,et al. Identification and purification of a very high affinity binding protein for toxic phospholipases A2 in skeletal muscle. , 1990, The Journal of biological chemistry.
[41] D. Hackel,et al. Production of Nephrotic Syndrome in Rats by Freund's Adjuvants and Rat Kidney Suspensions.∗ , 1959, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[42] M. Murakami,et al. This information is current as Inflammation Exacerbates Ovalbumin-Induced Lung Receptor 2 Deficiency of Phospholipase , 2013 .
[43] M. Serrano,et al. Senescence in tumours: evidence from mice and humans , 2010, Nature Reviews Cancer.
[44] V. Guigonis,et al. [Anti-CD10 fetomaternal alloimmunisation]. , 2009, Medecine sciences : M/S.